323 related articles for article (PubMed ID: 18326929)
1. Rechallenge with cisplatin in a patient with pancreatic cancer who developed a hypersensitivity reaction to oxaliplatin. Is skin test useful in this setting?
Elligers KT; Davies M; Sanchis D; Ferencz T; Saif MW
JOP; 2008 Mar; 9(2):197-202. PubMed ID: 18326929
[TBL] [Abstract][Full Text] [Related]
2. Variant hypersensitivity reaction (HSR) presented with persistent dry cough after receiving oxaliplatin in a pancreatic cancer patient.
Li J; Peccerillo J; Kaley K; Saif MW
Iran J Allergy Asthma Immunol; 2009 Sep; 8(3):165-8. PubMed ID: 20124609
[TBL] [Abstract][Full Text] [Related]
3. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience.
Polyzos A; Tsavaris N; Gogas H; Souglakos J; Vambakas L; Vardakas N; Polyzos K; Tsigris C; Mantas D; Papachristodoulou A; Nikiteas N; Karavokyros JG; Felekouras E; Griniatsos J; Giannopoulos A; Kouraklis G
Oncology; 2009; 76(1):36-41. PubMed ID: 19033714
[TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin hypersensitivity: case report and successful repeat desensitization.
Edmondson DA; Gruling BJ; Urmanski AM; Wong SJ; Levy MB
Am J Ther; 2007; 14(1):116-8. PubMed ID: 17303980
[TBL] [Abstract][Full Text] [Related]
5. Successful desensitization to oxaliplatin.
Mis L; Fernando NH; Hurwitz HI; Morse MA
Ann Pharmacother; 2005 May; 39(5):966-9. PubMed ID: 15784807
[TBL] [Abstract][Full Text] [Related]
6. Desensitization to oxaliplatin with two stages of premedication in a patient with metastatic rectal cancer.
Nozawa H; Muto Y; Yamada Y
Clin Ther; 2008 Jun; 30(6):1160-5. PubMed ID: 18640472
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and predictive value of skin testing in platinum salt hypersensitivity.
Leguy-Seguin V; Jolimoy G; Coudert B; Pernot C; Dalac S; Vabres P; Collet E
J Allergy Clin Immunol; 2007 Mar; 119(3):726-30. PubMed ID: 17258305
[TBL] [Abstract][Full Text] [Related]
8. Standardization of skin tests for diagnosis and prevention of hypersensitivity reactions to oxaliplatin.
Pagani M; Bonadonna P; Senna GE; Antico A
Int Arch Allergy Immunol; 2008; 145(1):54-7. PubMed ID: 17703101
[TBL] [Abstract][Full Text] [Related]
9. Administration of cisplatin in three patients with carboplatin hypersensitivity: is skin testing useful?
Syrigou E; Makrilia N; Vassias A; Nikolaidis I; Xyla V; Manolopoulos L; Syrigos K
Anticancer Drugs; 2010 Mar; 21(3):333-8. PubMed ID: 20038831
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin-associated hypersensitivity reactions: clinical presentation and management.
Hewitt MR; Sun W
Clin Colorectal Cancer; 2006 Jul; 6(2):114-7. PubMed ID: 16945166
[TBL] [Abstract][Full Text] [Related]
11. Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review.
Kim BH; Bradley T; Tai J; Budman DR
Oncology; 2009; 76(4):231-8. PubMed ID: 19246947
[TBL] [Abstract][Full Text] [Related]
12. Hypersensitivity and idiosyncratic reactions to oxaliplatin.
Thomas RR; Quinn MG; Schuler B; Grem JL
Cancer; 2003 May; 97(9):2301-7. PubMed ID: 12712487
[TBL] [Abstract][Full Text] [Related]
13. Management of allergic reactions to oxaliplatin in colorectal cancer patients.
Suenaga M; Mizunuma N; Shinozaki E; Matsusaka S; Chin K; Muto T; Konishi F; Hatake K
J Support Oncol; 2008; 6(8):373-8. PubMed ID: 19149322
[TBL] [Abstract][Full Text] [Related]
14. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma.
Ottaiano A; Tambaro R; Greggi S; Prato R; Di Maio M; Esposito G; Scala F; Barletta E; Losito S; De Vivo R; Iaffaioli VR; Pignata S
Anticancer Res; 2003; 23(4):3465-8. PubMed ID: 12926091
[TBL] [Abstract][Full Text] [Related]
15. Successful rechallenge for oxaliplatin hypersensitivity reactions in patients with metastatic colorectal cancer.
Yanai T; Iwasa S; Hashimoto H; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Yamamoto H
Anticancer Res; 2012 Dec; 32(12):5521-6. PubMed ID: 23225461
[TBL] [Abstract][Full Text] [Related]
16. Does OPTIMOX strategy ("stop-and-go" approach) also work in treatment of pancreatic cancer with oxaliplatin-based regimens?
Saif MW
JOP; 2008 Sep; 9(5):658-63. PubMed ID: 18762700
[TBL] [Abstract][Full Text] [Related]
17. Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience.
Mir O; Alexandre J; Ropert S; Montheil V; Martin I; Durand JP; Goldwasser F
Anticancer Drugs; 2009 Feb; 20(2):105-8. PubMed ID: 19209026
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity.
Shord SS; Bernard SA; Lindley C; Blodgett A; Mehta V; Churchel MA; Poole M; Pescatore SL; Luo FR; Chaney SG
Anticancer Res; 2002; 22(4):2301-9. PubMed ID: 12174918
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.
Novarino A; Satolli MA; Chiappino I; Giacobino A; Bellone G; Rahimi F; Milanesi E; Bertetto O; Ciuffreda L
Am J Clin Oncol; 2009 Feb; 32(1):44-8. PubMed ID: 19194124
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity.
Taylor SE; Beck TL; Krivak TC; Zorn KK; Kelley JL; Edwards RP
Gynecol Oncol; 2014 Jul; 134(1):68-72. PubMed ID: 24769036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
